Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Becton, Dickinson and Company for the period ended March 31, 1996. The company operates in the Medical Supplies and Devices and Diagnostic Systems segments. The report covers the three and six months ended March 31, 1996, compared to the same periods in 1995.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 1996 | Six Months Ended Mar 31, 1996 |
|---|---|---|
| Revenues | $705.7 million | $1,345.7 million |
| Net Income | $74.8 million | $119.3 million |
| Earnings Per Share (EPS) | $1.10 | $1.75 |
| Operating Income | $112.8 million | $184.7 million |
| Gross Profit Margin | 47.8% | 46.7% |
| Operating Margin | 16.0% | 13.7% |
| Cash from Operations (6mo) | $179.2 million | |
| Short-Term Debt | $262.6 million (as of Mar 31, 1996) | |
| Long-Term Debt | $488.0 million (as of Mar 31, 1996) | |
| Cash and Equivalents | $156.6 million (as of Mar 31, 1996) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 1996 revenues increased 2% year-over-year. Adjusted for divestitures (glove business, contract packaging, surgical line), organic growth was approximately 7%. Six-month revenues grew 5% (3% excluding currency effects).
- Profitability: Net income rose 15% in Q2 and 21% for the six-month period. EPS increased 20% in Q2 and 27% for the six months, driven by operating income growth and share repurchases.
- Margins: Gross profit margin improved to 47.8% in Q2 (from 46.6% prior year) due to productivity gains and product mix. Operating margin improved to 16.0% in Q2.
- Divestitures: The company sold its contract packaging business in February 1996, recognizing a pre-tax gain of approximately $2 million. This, along with prior divestitures, negatively impacted reported revenue growth.
- Debt Reduction: Total debt decreased by $13 million during the first six months. The debt-to-capitalization ratio dropped to 36.0% from 38.0% a year ago.
Guidance, Outlook, and Risks
- Share Repurchases: The company repurchased 2.1 million shares for $160 million in the first six months. Management expects to spend approximately $300 million on repurchases for the full year. Authorization remains for an additional 1.9 million shares.
- Capital Expenditures: CapEx was $62 million for the first six months; full-year expectations are approximately $150 million.
- Dividends: The quarterly dividend was increased to $0.23 per share (from $0.205).
- Unusual Items: A $6 million charge was recorded to write off intangibles associated with a small medical product line the company decided to exit. Additionally, a $2 million gain was recognized from the sale of the contract packaging business.
- Risks/Contingencies: The company is assessing the impact of FASB Statement No. 121 regarding impairment of long-lived assets, though no material impact is expected. Domestic Diagnostic revenues continue to face pressure from cost containment initiatives in the marketplace.
Investor Verification Checklist
- Verify the impact of divestitures on organic revenue growth rates (reported 2% vs. adjusted ~7%).
- Confirm the sustainability of the improved gross profit margin (47.8%) amidst cost containment pressures in the domestic diagnostic market.
- Monitor the execution of the $300 million share repurchase program and its effect on future EPS.
- Review the $6 million intangible write-off to ensure no further impairment charges are anticipated under FASB Statement No. 121.
- Assess the company's liquidity position given the $160 million cash outflow for share buybacks and $62 million in capital expenditures.